U.S. Senators Request PTO Action on Patent Thickets



On June 8, 2022, a bipartisan group of U.S. Senators sent a letter to Kathi Vidal, Director of the U.S. Patent & Trademark Office, requesting that the PTO take action on patent thickets.  According to the Senators, “large numbers of patents cover a single product or minor variations on a single product, commonly known as patent thickets” that “negatively impacts millions of Americans.”  The Senators quoted a recent statement by President Biden that patent thickets “have been misused to inhibit or delay—for years and even decades—competition from generic drugs and biosimilars, denying Americans access to lower cost drugs.”  According to the Senators, “[i]n the drug industry, with the most minor, even cosmetic, tweaks to delivery mechanisms, dosages, and formulations, companies are able to obtain dozens or hundreds of patents for a single drug,” and “[t]his practice impedes generic drugs’ production, hurts competition, and can even extend exclusivity beyond the  congressionally mandated patent term.”

The Senators expressed specific concern about the prevalence of “continuation and other highly similar patents.”  According to the Senators, the “Patent Act envisions a single patent per invention, not a large portfolio based on one creation,” whereas “continuations now account for almost a quarter of all patent filings.”

The Senators presented a list of questions to the Patent Office and requested that the Patent Office issue a notice of proposed rulemaking or a public request for comments regarding those questions by September 1, 2022.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.